Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung
February 13, 2024 07:00 ET
|
Krystal Biotech, Inc.
• FDA clears IND and Phase 1 (KYANITE-1) clinical trial expected to be initiated in 1H 2024 PITTSBURGH, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a...
Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa
February 08, 2024 07:00 ET
|
Krystal Biotech, Inc.
• Initial clinical data suggest the potential of B-VEC to treat lesions in the eye of DEB patients and additional applications of Krystal’s HSV-1 platform to treat ocular diseases • Repeat...
Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference
February 01, 2024 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the...
Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®
January 04, 2024 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and...
Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)
December 19, 2023 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and...
Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa
November 27, 2023 07:00 ET
|
Krystal Biotech, Inc.
If approved, ~3,000 people with DEB in the European Union could receive VYJUVEK to treat the underlying cause of the disease for the first timeVYJUVEK received Orphan Drug Designation and PRIME...
Krystal Biotech to Present at the Stifel 2023 Healthcare Conference
November 09, 2023 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and...
Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update
November 06, 2023 07:00 ET
|
Krystal Biotech, Inc.
• 284 VYJUVEK Patient Start Forms and $8.6 million in VYJUVEK U.S. net product revenue as of the end of the third quarter • Cohort 1 completed in Phase 1 clinical trial of KB407 for the treatment...
Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023
October 30, 2023 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and...
Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference
September 28, 2023 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and...